Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

PHASE4CompletedINTERVENTIONAL
Enrollment

712

Participants

Timeline

Start Date

October 23, 2013

Primary Completion Date

November 22, 2016

Study Completion Date

May 29, 2017

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Ranibizumab

0.5 mg intravitreal injection

DRUG

Aflibercept

2 mg intravitreal injection

Trial Locations (68)

1020

Novartis Investigative Site, Laken

1090

Novartis Investigative Site, Vienna

1204

Novartis Investigative Site, Geneva

1708

Novartis Investigative Site, Fribourg

2600

Novartis Investigative Site, Glostrup Municipality

3000

Novartis Investigative Site, Leuven

3010

Novartis Investigative Site, Bern

4000

Novartis Investigative Site, Roskilde

4800

Novartis Investigative Site, Arendal

5020

Novartis Investigative Site, Salzburg

10713

Novartis Investigative Site, Berlin

12203

Novartis Investigative Site, Berlin

20246

Novartis Investigative Site, Hamburg

21034

Novartis Investigative Site, Dijon

24105

Novartis Investigative Site, Kiel

28213

Novartis Investigative Site, Bremen

35039

Novartis Investigative Site, Marburg

37075

Novartis Investigative Site, Göttingen

38442

Novartis Investigative Site, Wolfsburg

40225

Novartis Investigative Site, Düsseldorf

45147

Novartis Investigative Site, Essen

45468

Novartis Investigative Site, Mülheim

48145

Novartis Investigative Site, Münster

48149

Novartis Investigative Site, Münster

49214

Novartis Investigative Site, Bad Rothenfelde

50924

Novartis Investigative Site, Cologne

50935

Novartis Investigative Site, Cologne

53127

Novartis Investigative Site, Bonn

53721

Novartis Investigative Site, Siegburg

55131

Novartis Investigative Site, Mainz

58097

Novartis Investigative Site, Hagen

60590

Novartis Investigative Site, Frankfurt

64297

Novartis Investigative Site, Darmstadt

66280

Novartis Investigative Site, Sulzbach

66421

Novartis Investigative Site, Homburg

72076

Novartis Investigative Site, Tübingen

72189

Novartis Investigative Site, Västerås

75010

Novartis Investigative Site, Paris

75015

Novartis Investigative Site, Paris

79106

Novartis Investigative Site, Freiburg im Breisgau

81675

Novartis Investigative Site, München

89075

Novartis Investigative Site, Ulm

93053

Novartis Investigative Site, Regensburg

94000

Novartis Investigative Site, Créteil

95444

Novartis Investigative Site, Bayreuth

97080

Novartis Investigative Site, Würzburg

4710243

Novartis Investigative Site, Braga

A-6807

Novartis Investigative Site, Feldkirch

A-8036

Novartis Investigative Site, Graz

A-4020

Novartis Investigative Site, Linz

A-1130

Novartis Investigative Site, Vienna

F-75571

Novartis Investigative Site, Paris

09113

Novartis Investigative Site, Chemnitz

08371

Novartis Investigative Site, Glauchau

04103

Novartis Investigative Site, Leipzig

5223 GZ

Novartis Investigative Site, 's-Hertogenbosch

1105 AZ

Novartis Investigative Site, Amsterdam

6500 HB

Novartis Investigative Site, Nijmegen

0264

Novartis Investigative Site, Oslo

3000-354

Novartis Investigative Site, Coimbra

3030-163

Novartis Investigative Site, Coimbra

1050-078

Novartis Investigative Site, Lisbon

1050-085

Novartis Investigative Site, Lisbon

4099-001

Novartis Investigative Site, Porto

4200 319

Novartis Investigative Site, Porto

2600-009

Novartis Investigative Site, Vila Franca de Xira

4434 502

Novartis Investigative Site, Vila Nova de Gaia

112 82

Novartis Investigative Site, Stockholm

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY